Healthcare
ByCan Bristol Myers Squibb’s Enterprise-Wide Rollout of Anthropic’s Claude to 30,000 Employees Unlock Billions in AI-Driven Value and Redefine Biopharma’s Digital Future?
Key Highlights From AI Investment to Business Value Creation Bristol Myers Squibb’s enterprise-wide adoption of Anthropic’s Claude represents…
Can Edison Scientific and Population Health Partners’ AI Build the Next $10 Billion Biotech?
Key Highlights The Deal at a Glance Announced on June 29, 2026, the partnership pairs PHP’s proven track…
Can Sanofi SA’s New AI-Enabled Innovation Hub in China Accelerate Global Drug Development and Reshape Biopharma Operations Across Asia?
Key Highlights: AI-Integrated Innovation Hubs Redefine Global R&D ModelsSanofi SA’s launch of its innovation and operations centre in…
Can Sanofi SA’s $1.2 Billion AI-Driven Autoimmune Alliance with Kali Therapeutics Inc Unlock Next-Gen Tri-Specific Antibody Therapies and Disrupt Immunology Markets?
Key Highlights: AI-Powered Biologics Platforms Accelerate Next-Gen Antibody DiscoverySanofi SA’s licensing agreement with Kali Therapeutics Inc highlights the…
Can Novo Nordisk’s Lawsuit Against Eli Lilly Push the $100 Billion GLP-1 Market Toward More Transparent, Evidence-Based Advertising?
Key Highlights A Landmark Legal Moment Reinforcing Standards in Patient-Facing Advertising Novo Nordisk’s decision to formally challenge Eli…
Roche’s Gazyva Wins Second FDA Priority Review in Months — Is Obinutuzumab Becoming Nephrology’s Next Blockbuster?
Key Highlights A Landmark Regulatory Milestone for a Disease With No Approved Treatments Roche’s announcement that the FDA…
